Effects of Comedication on the Serum Levels of Aripiprazole: Evidence from a Routine Therapeutic Drug Monitoring Service

Abstract

Introduction: The objective of the study was to compare the serum concentrations of the atypical antipsychotic aripiprazole in monotherapy with the concentrations found during concomitant therapy with other drugs.

Methods: Samples analyzed for aripiprazole by a liquid chromatography-mass spectrometry method in a routine therapeutic drug monitoring setting were collected consecutively.

Results: Samples from 81 patients were included in the study. Comedication with the CYP3A4 inducer carbamazepine lowered the dose-adjusted aripiprazole concentration by 88%. Comedication with CYP2D6 inhibitors gave a mean concentration 44% higher than in the monotherapy group. Subjects comedicated with valproate had lower aripiprazole concentrations, while subjects comedicated with lamotrigine, citalopram/escitalopram and lithium had higher concentrations than the subjects in the monotherapy group.

Conclusion: Although the study is small and the results should be interpreted very cautiously, it indicates that comedication with drugs inhibiting or inducing CYP2D6 or CYP3A4 affects the serum concentrations of aripiprazole. The other findings should be considered as preliminary and have to be replicated in a larger setting before firm conclusions can be drawn.

Key words

aripiprazole - therapeutic drug monitoring - drug interactions

References

• 1 Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors.  J Affective Disord. 2005;  86 99-104
• 2 Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.  Eur Neuropsychopharmacol. 2001;  11 275-283
• 3 Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharma- cokinetics of aripiprazole and concomitant lithium and valproate.  J Clin Pharmacol. 2005;  45 89-93
• 4 Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.  J Clin Psychitary. 2005;  66 49-51
• 5 Dickens M, Chen C. Lamotrigine. Chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors, Antiepileptic drugs. Philadelphia: Lippincott Williams & Wilkins 2002: 370-379
• 6 El-Sayeh H, Morganti C. Aripiprazole for schizophrenia.  Cochrane Database Syst Rev. 2004;  , CD004578.pub2
• 7 El-Sayeh H, Morganti C. Aripiprazole for schizophrenia.  Cochrane Database Syst Rev. 2006;  , CD004578
• 8 Grunder G, Kugel M, Ebrecht M, Gorocs T, Modell S. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.  Pharmacopsychiatry. 2006;  39 ((Suppl 1)) 21-25
• 9 Hiemke C, Draqievic A, Grunder G, Hatter S, Sachse J, Vernaleken I. et al . Therapeutic drug monitoring of new antipsychotic drugs.  Ther Drug Monit. 2004;  26 156-160
• 10 http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=18494
• 11 Kane JM, Carson WH, Saha AR, McQuade RD, Ingento GG, Zimbroff DL. et al . Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.  J Clin Psychiatry. 2002;  63 763-771
• 12 Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM. et al . For the aripiprazole study group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.  J Clin Psychiatry. 2006;  67 626-637
• 13 Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T. et al . Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole.  Drug Metab Pharmacokinet. 2005;  20 55-64
• 14 Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.  J Clin Pharmacol. 2004;  44 179-187
• 15 McGavin JK, Goa KL. Aripiprazole.  CNS Drugs. 2002;  16 779-786
• 16 Nickel MK, Muehlbacher M, Nickel C, Kettler C, Gil FP, Bachler E. et al . Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.  Am J Psychiatry. 2006;  163 833-838
• 17 Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE. et al . Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.  J Clin Psychiatry. 2005;  66 1326-1330
• 18 von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.  Drug Metab Dispos. 2001;  29 1102-1109

Correspondence